2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

Catalog No. :
ACNQEQ769
CAS No. :
2223035-26-3
Molecular Formula :
C13H19BN2O2
Molecular Weight :
246.15

IUPAC Name:2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$2252.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
IUPAC Name2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
MDL No.MFCD11223346
Molecular FormulaC13H19BN2O2
Molecular Weight246.15
SMILESCC(C)(C(C)(C)O1)OB1C2=NC=C(C3CC3)N=C2
InChI KeyBLTOSEPJCJZPAA-UHFFFAOYSA-N
Synonym2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine;Pyrazine, 2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2223035-26-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACNQEQ769 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAQNU854 route compound structure diagram
    ACAQNU854411235-57-9 In Stock
  4. Then
  5. ACNQEQ769 route product structure diagram
    ACNQEQ7692223035-26-3
Inquiry

2. ACNQEQ769 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKRCI918 route compound structure diagram
    ACKRCI9181086382-78-6 In Stock
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACNQEQ769 route product structure diagram
    ACNQEQ7692223035-26-3
Inquiry

Comments (0)